Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trialJane C. Burns, Nichole Samuy, Beth F. Printz et al.|The Lancet Child & Adolescent Health|2021Cited by 113
Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United StatesJennifer Burney, Archana Chatterjee, Samantha C. Roberts et al.|JAMA Network Open|2022Cited by 52